122 related articles for article (PubMed ID: 21795655)
1. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.
de Groot M; Aronica E; Heimans JJ; Reijneveld JC
Neurology; 2011 Aug; 77(6):532-9. PubMed ID: 21795655
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
[TBL] [Abstract][Full Text] [Related]
3. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
[TBL] [Abstract][Full Text] [Related]
4. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study.
Rosati A; Buttolo L; Stefini R; Todeschini A; Cenzato M; Padovani A
Arch Neurol; 2010 Mar; 67(3):343-6. PubMed ID: 20212232
[TBL] [Abstract][Full Text] [Related]
6. Rare protein sequence variation in SV2A gene does not affect response to levetiracetam.
Dibbens LM; Hodgson BL; Helbig KL; Oliver KL; Mulley JC; Berkovic SF; Scheffer IE
Epilepsy Res; 2012 Sep; 101(3):277-9. PubMed ID: 22551666
[TBL] [Abstract][Full Text] [Related]
7. A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.
Stockburger C; Miano D; Baeumlisberger M; Pallas T; Arrey TN; Karas M; Friedland K; Müller WE
J Alzheimers Dis; 2016; 50(1):201-15. PubMed ID: 26639968
[TBL] [Abstract][Full Text] [Related]
8. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
Serajee FJ; Huq AM
Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
[TBL] [Abstract][Full Text] [Related]
9. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.
de Groot M; Toering ST; Boer K; Spliet WG; Heimans JJ; Aronica E; Reijneveld JC
Neuro Oncol; 2010 Mar; 12(3):265-73. PubMed ID: 20167814
[TBL] [Abstract][Full Text] [Related]
10. Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy.
Specchio N; Boero G; Michelucci R; Gambardella A; Giallonardo AT; Fattouch J; Di Bonaventura C; de Palo A; Ladogana M; Lamberti P; Vigevano F; La Neve A; Specchio LM
Epilepsia; 2008 Apr; 49(4):663-9. PubMed ID: 18266754
[TBL] [Abstract][Full Text] [Related]
11. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
[TBL] [Abstract][Full Text] [Related]
12. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F
Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812
[TBL] [Abstract][Full Text] [Related]
13. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.
Toering ST; Boer K; de Groot M; Troost D; Heimans JJ; Spliet WG; van Rijen PC; Jansen FE; Gorter JA; Reijneveld JC; Aronica E
Epilepsia; 2009 Jun; 50(6):1409-18. PubMed ID: 19220410
[TBL] [Abstract][Full Text] [Related]
14. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
Gillard M; Chatelain P; Fuks B
Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
[TBL] [Abstract][Full Text] [Related]
15. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y
Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049
[TBL] [Abstract][Full Text] [Related]
16. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam monotherapy in children with epilepsy.
Khurana DS; Kothare SV; Valencia I; Melvin JJ; Legido A
Pediatr Neurol; 2007 Apr; 36(4):227-30. PubMed ID: 17437904
[TBL] [Abstract][Full Text] [Related]
18. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.
Kaminski RM; Matagne A; Leclercq K; Gillard M; Michel P; Kenda B; Talaga P; Klitgaard H
Neuropharmacology; 2008 Mar; 54(4):715-20. PubMed ID: 18207204
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
Rosenfeld WE; Benbadis S; Edrich P; Tassinari CA; Hirsch E
Epilepsy Res; 2009 Jul; 85(1):72-80. PubMed ID: 19327967
[TBL] [Abstract][Full Text] [Related]
20. Visualization of SV2A conformations in situ by the use of Protein Tomography.
Lynch BA; Matagne A; Brännström A; von Euler A; Jansson M; Hauzenberger E; Söderhäll JA
Biochem Biophys Res Commun; 2008 Oct; 375(4):491-5. PubMed ID: 18692481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
